CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0555
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Kim1, RD; Sarker, D; Meyer, T; Yau, T; Macarulla, T; Park, JW; Choo, SP; Hollebecque, A; Sung, MW; Lim, HY; Mazzaferro, V; Trojan, J; Zhu, AX; Yoon, JH; Sharma, S; Lin, ZZ; Chan, SL; Faivre, S; Feun, LG; Yen, CJ; Dufour, JF; Palmer, DH; Llovet, JM; Manoogian, M; Tugnait, M; Stransky, N; Hagel, M; Kohl, NE; Lengauer, C; Sherwin, CA; Schmidt-Kittler, O; Hoeflich, KP; Shi, HL; Wolf, BB; Kang, YK

Cancer Med 2019 10.1002/cam4.2570
Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
Yu1, JI; Lee, SJ; Lee, J; Lim, HY; Paik, SW; Yoo, GS; Choi, C; Park, HC

Front Oncol 2019 10.3389/fonc.2019.01327
Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening
Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J

SCI REP-UK 2019 10.1038/s41598-019-51981-5
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C

J Cancer 2019 10.7150/jca.37610
Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY

CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK

J IMMUNOTHER 2019 10.1097/CJI.0000000000000283
LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target
Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST

ANTICANCER RES 2019 10.21873/anticanres.13785
Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer
Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

Transl Cancer Res 2019 10.21037/tcr.2019.09.27
Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

CANCER RES TREAT 2019 10.4143/crt.2018.401
Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols
Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K

CANCER RES TREAT 2019 10.4143/crt.2018.379
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK

Am J Transl Res 2019
Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification
Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J

ONCOLOGIST 2019 10.1634/theoncologist.2018-0838
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
El Dika1, I; Lim, HY; Yong, WP; Lin, CC; Yoon, JH; Modiano, M; Freilich, B; Choi, HJ; Chao, TY; Kelley, RK; Brown, J; Knox, J; Ryoo, BY; Yau, T; Abou-Alfa, GK

INVEST NEW DRUG 2019 10.1007/s10637-018-0707-5
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma
Yoo1, C; Park, JW; Kim, YJ; Kim, DY; Yu, SJ; Lim, TS; Lee, SJ; Ryoo, BY; Lim, HY

J Cancer 2019 10.7150/jca.30355
The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

ANN ONCOL 2019 10.1093/annonc/mdz058
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY

CANCER RES TREAT 2019 10.4143/crt.2018.226
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Yoo1, C; Kang, J; Lim, HY; Kim, JH; Lee, MA; Lee, KH; Kim, TY; Ryoo, BY

TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J

CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
Oh1, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H

J Cancer 2019 10.7150/jca.29106
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

LANCET ONCOL 2019 10.1016/S1470-2045(18)30937-9
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Zhu1, AX; Kang, YK; Yen, CJ; Finn, RS; Galle, PR; Llovet, JM; Assenat, E; Brandi, G; Pracht, M; Lim, HY; Rau, KM; Motomura, K; Ohno, I; Merle, P; Daniele, B; Shin, DB; Gerken, G; Borg, C; Hiriart, JB; Okusaka, T; Morimoto, M; Hsu, YZ; Abada, PB; Kudo, M

OncoTargets and therapy 2019 10.2147/OTT.S187621
The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

PLoS One 2019 10.1371/journal.pone.0210730
Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients
Sinn1, DH; Choi, GS; Park, HC; Kim, JM; Kim, H; Song, KD; Kang, TW; Lee, MW; Rhim, H; Hyun, D; Cho, SK; Shin, SW; Jeong, WK; Kim, SH; Il Yu, J; Ha, SY; Lee, SJ; Lim, HY; Kim, K; Ahn, JH; Kang, W; Gwak, GY; Paik, YH; Choi, MS; Lee, JH; Koh, KC; Joh, JW; Lim, HK; Paik, SW

INVEST NEW DRUG 2018 10.1007/s10637-018-0658-x
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
Tak1, WY; Ryoo, BY; Lim, HY; Kim, DY; Okusaka, T; Ikeda, M; Hidaka, H; Yeon, JE; Mizukoshi, E; Morimoto, M; Lee, MA; Yasui, K; Kawaguchi, Y; Heo, J; Morita, S; Kim, TY; Furuse, J; Katayama, K; Aramaki, T; Hara, R; Kimura, T; Nakamura, O; Kudo, M

J Gastric Cancer 2018 10.5230/jgc.2018.18.e34
Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH

BMC CANCER 2018 10.1186/s12885-018-4995-0
Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line
Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO

RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002
Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer
Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

CLIN CANCER RES 2018 10.1158/1078-0432.CCR-17-3588
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Lim1, HY; Merle, P; Weiss, KH; Yau, T; Ross, P; Mazzaferro, V; Blanc, JF; Ma, YT; Yen, CJ; Kocsis, J; Choo, SP; Sukeepaisarnjaroen, W; Gerolami, R; Dufour, JF; Gane, EJ; Ryoo, BY; Peck-Radosavljevic, M; Dao, T; Yeo, W; Lamlertthon, W; Thongsawat, S; Teufel, M; Roth, K; Reis, D; Childs, BH; Krissel, H; Llovet, JM

NAT MED 2018 10.1038/s41591-018-0101-z
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK

J Cancer 2018 10.7150/jca.26068
Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013
c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival
Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

J Cancer 2018 10.7150/jca.24948
Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005
Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer
Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS

ANN ONCOL 2018 10.1093/annonc/mdy101
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
Abou-Alfa1, GK; Qin, S; Ryoo, BY; Lu, SN; Yen, CJ; Feng, YH; Lim, HY; Izzo, F; Colombo, M; Sarker, D; Bolondi, L; Vaccaro, G; Harris, WP; Chen, Z; Hubner, RA; Meyer, T; Sun, W; Harding, JJ; Hollywood, EM; Ma, J; Wan, PJ; Ly, M; Bomalaski, J; Johnston, A; Lin, CC; Chao, Y; Chen, LT

J HEMATOL ONCOL 2018 10.1186/s13045-018-0617-1
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
Guo1, J; Jin, J; Oya, M; Uemura, H; Takahashi, S; Tatsugami, K; Rha, SY; Lee, JL; Chung, J; Lim, HY; Wu, HC; Chang, YH; Azad, A; Davis, ID; Carrasco-Alfonso, MJ; Nanua, B; Han, J; Ahmad, Q; Motzer, R

TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007
The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY

CANCER RES TREAT 2018 10.4143/crt.2016.584
Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
Jung1, KS; Lee, SJ; Park, SH; Lee, JL; Lee, SH; Lim, JY; Kang, JH; Lee, S; Rha, SY; Lee, KH; Kim, HY; Lim, HY

J Cancer 2018 10.7150/jca.25132
The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO

KOREAN JOURNAL OF INTERNAL MEDICINE 2018 10.3904/kjim.2015.162
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
Kim1, MJ; Kim, YS; Oh, SY; Lee, S; Choi, YJ; Seol, YM; Park, MJ; Kim, KH; Park, LC; Kang, JH; Hwang, IG; Lee, SI; Lim, ST; Kim, HS; Lim, HY; Rha, SY; Kim, HJ

TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.008
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
Lee1, JY; Kim, K; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Kwon, GY; Kim, KM; Lee, J; Lim, HY; Park, SH

CANCER RES TREAT 2018 10.4143/crt.2016.535
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
Choi1, Y; Yun, MS; Lim, SH; Lee, J; Ahn, JH; Kim, YJ; Park, KH; Park, YS; Lim, HY; An, H; Suh, DC; Kim, YH

J CLIN ONCOL 2017 10.1200/JCO.2017.73.5324
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Motzer1, RJ; Haas, NB; Donskov, F; Gross-Goupil, M; Varlamov, S; Kopyltsov, E; Lee, JL; Melichar, B; Rini, BI; Choueiri, TK; Zemanova, M; Wood, LA; Reaume, MN; Stenzl, A; Chowdhury, S; Lim, HY; McDermott, R; Michael, A; Bao, WC; Carrasco-Alfonso, MJ; Aimone, P; Voi, M; Doehn, C; Russo, P; Sternberg, CN

INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS

ONCOTARGET 2017 10.18632/oncotarget.22394
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.22511
Elevated CEA is associated with worse survival in recurrent rectal cancer
Cho1, WK; Choi, DH; Park, HC; Park, W; Yu, JI; Park, YS; Park, JO; Lim, HY; Kang, WK; Kim, HC; Cho, YB; Yun, SH; Lee, WY

ONCOTARGET 2017 10.18632/oncotarget.3750
MerTK is a novel therapeutic target in gastric cancer
Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J

ONCOLOGIST 2017 10.1634/theoncologist.2017-0020
Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials
Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.20492
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.18168
The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

TRANSL ONCOL 2017 10.1016/j.tranon.2017.03.001
Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model
Jang1, J; Kim, HK; Bang, H; Kim, ST; Kim, SY; Park, SH; Lim, HY; Kang, WK; Lee, J; Kim, KM

BMC UROL 2017 10.1186/s12894-017-0253-z
A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
Kim1, HS; Lee, JY; Lee, SJ; Lim, HY; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Park, SH

J Cancer 2017 10.7150/jca.18286
The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS

J Cancer 2017 10.7150/jca.19458
The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
Kim1, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST

J Cancer 2017 10.7150/jca.19582
MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines
Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Lencioni R11, Montal R2, Torres F3, Park JW4, Decaens T5, Raoul JL6, Kudo M7, Chang C8, Rios J3, Boige V9, Assenat E10, Kang YK11, Lim HY12, Walters I13, Llovet JM14.

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6.
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.

Asia Pac J Clin Oncol. 2017 Feb;13(1):61-67. doi: 10.1111/ajco.12465. Epub 2016 Mar 31.
Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma
Lim SH11, Hwang IG2, Ji JH3, Oh SY4, Yi JH5, Lim DH6, Lim HY1, Lee SJ1, Park SH1.

Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362.
Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer
Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.

J Cancer. 2017 Feb 25;8(5):730-736. doi: 10.7150/jca.17887. eCollection 2017.
An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients
Lee JY11, Hong M2, Lee J3, Lee S3, Kim KM2, Park C4, Lim HY3.

Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009.
Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma
Cho J11, Lee J1, Kim J1, Kim ST1, Lee S1, Kim SY1, Ha SY2, Park CK3, Lim HY4.

Hepatology. 2016 Sep;64(3):774-84. doi: 10.1002/hep.28600. Epub 2016 May 17.
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Cheng AL11, Thongprasert S2, Lim HY3, Sukeepaisarnjaroen W4, Yang TS5, Wu CC6, Chao Y7, Chan SL8, Kudo M9, Ikeda M10, Kang YK11, Pan H12, Numata K13, Han G14, Balsara B15, Zhang Y15, Rodriguez AM16, Zhang Y15, Wang Y15, Poon RT17.

BMC Urol. 2016 Aug 2;16(1):46. doi: 10.1186/s12894-016-0163-5.
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Kim MJ11, Park SH2, Lee JL3, Lee SH4, Lee SJ5, Lim HY5.

Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523.
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis
Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16.
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)
Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.

J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.
Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.

Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10.
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.

Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526.
Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment
Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.

Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175.
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.

J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016.
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.

BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4.
The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis
Kim HS11,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.

Clin Genitourin Cancer. 2016 Feb;14(1):76-81. doi: 10.1016/j.clgc.2015.09.008. Epub 2015 Sep 25.
A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma
Kim YS11, Lee SI2, Park SH3, Park S3, Hwang IG4, Lee SC5, Sun JM3, Lee J3, Lim HY3.

Tumori. 2016 Jan-Feb;102(1):114-21. doi: 10.5301/tj.5000439. Epub 2015 Oct 7.
Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery
Kim TG11, Park W2, Choi DH2, Park HC2, Kim SH3, Cho YB4, Yun SH4, Kim HC4, Lee WY4, Lee J5, Park JO5, Park YS5, Lim HY5, Kang WK5, Chun HK6.

Ann Oncol. 2015 Dec;26(12):2457-63. doi: 10.1093/annonc/mdv388. Epub 2015 Sep 18.
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
Kang YK11, Yau T2, Park JW3, Lim HY4, Lee TY5, Obi S6, Chan SL7, Qin S8, Kim RD9, Casey M10, Chen C11, Bhattacharyya H11, Williams JA12, Valota O13, Chakrabarti D10, Kudo M14.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.

Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432.
PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.

Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494.
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line
Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.

Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27.
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.

J Hepatol. 2015 Oct;63(4):896-904. doi: 10.1016/j.jhep.2015.06.001. Epub 2015 Jun 10.
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
Cheng AL11, Kang YK2, He AR3, Lim HY4, Ryoo BY2, Hung CH5, Sheen IS6, Izumi N7, Austin T8, Wang Q9, Greenberg J9, Shiratori S9, Beckman RA10, Kudo M11; Investigators’ Study Group.

Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis
Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.

J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5.
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses
Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.

BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y.
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC

Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20.
Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial
Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.

Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151.
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer
Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.

Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627.
Patient-derived cell models as preclinical tools for genome-directed targeted therapy
Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.

Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15.
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Park SH11, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.

Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721.
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.

Oncotarget. 2015 Sep 15;6(27):24320-32.
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.

Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001.
Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer
Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.

Cancer Chemother Pharmacol. 2015 Aug;76(2):257-67. doi: 10.1007/s00280-015-2787-7. Epub 2015 Jun 3.
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma
Kim MN11, Ro SW, Kim do Y, Kim da Y, Cho KJ, Park JH, Lim HY, Han KH.

Cancer Res Treat. 2015 Jul;47(3):343-61. doi: 10.4143/crt.2014.308. Epub 2015 May 18.
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Park JO11, Oh DY2, Hsu C3, Chen JS4, Chen LT5, Orlando M6, Kim JS7, Lim HY1.

Radiology. 2015 Jul;276(1):274-85. doi: 10.1148/radiol.15141215. Epub 2015 Feb 25.
Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance
Kang TW11, Lim HK1, Lee MW1, Kim YS1, Rhim H1, Lee WJ1, Gwak GY1, Paik YH1, Lim HY1, Kim MJ1.

BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y.
Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.

J Hepatol. 2015 May;62(5):1112-21. doi: 10.1016/j.jhep.2014.12.009. Epub 2014 Dec 13.
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome a